PMC:7795856 / 4919-5373
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
124 | 135-138 | Gene | denotes | Tα1 | Gene:134864 |
128 | 112-120 | Species | denotes | patients | Tax:9606 |
149 | 165-174 | Disease | denotes | mortality | MESH:D003643 |
150 | 185-193 | Disease | denotes | COVID-19 | MESH:C000657245 |
151 | 212-227 | Disease | denotes | lymphocytopenia | MESH:D008231 |
161 | 334-337 | Gene | denotes | Tα1 | Gene:134864 |
162 | 432-435 | Gene | denotes | Tα1 | Gene:134864 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T14 | 212-227 | Phenotype | denotes | lymphocytopenia | http://purl.obolibrary.org/obo/HP_0001888 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T32 | 51-268 | Sentence | denotes | Furthermore, a recent retrospective study in treated Chinese patients revealed that Tα1 significantly reduced the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells [23]. |
T33 | 269-388 | Sentence | denotes | However, there are two major drawbacks of the currently marketed Tα1, both of which are related to its peptidic nature. |
T34 | 389-451 | Sentence | denotes | First, the biopharmaceutical production of Tα1 is challenging. |